Published : 21 Jan 2026

---

After a productive JPM week including Biotech Showcase in San Francisco, Aagami has won its first new client of 2026, within few days.

 

Client is a US based clinical-stage pharmaceutical company developing therapies to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases.

 

Their clinical pipeline currently has two lead drug candidates, brilaroxazine and another. Both are new chemical entities discovered in-house using their chemical genomics driven technology platform.

 

Their lead asset brilaroxazine is in Phase 3 stage for Schizophrenia. Aagami has been hired to provide strategic advisory and key initiatives support. 

 

If you would like to know more, please contact us on action@aagami.com